BackCatabasis Pharmaceuticals Overview

Catabasis Pharmaceuticals Long Term Debt

Latest long-term debt for CATB: $3.1M.

Get informed when a big investor buys or sells

+ Follow
Long Term Debt
$3.06M

Peer average

Loading

Catabasis Pharmaceuticals Long Term Debt History

Loading

Catabasis Pharmaceuticals vs. peers: Long Term Debt Comparison

Loading

Catabasis Pharmaceuticals Long Term Debt Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Catabasis Pharmaceuticals (CATB) FAQ

As of the most recent data (September 2025), CATB shows a long-term debt of $3.1M. Scroll down for historical charts and peer comparison views.

Tracking CATB's long-term debt over time shows whether Catabasis Pharmaceuticals is scaling, shrinking, or reshaping that part of the business. The current reading is $3.1M Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this long-term debt page, Stockcircle has Catabasis Pharmaceuticals's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $3.1M) with ownership activity and broader fundamentals.

Catabasis Pharmaceuticals's long-term debt is $3.1M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.